Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

Hematologic Improvement-Neutrophil and -Platelet in the MEDALIST Trial: Multilineage Data from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions

Guillermo Garcia-Manero, MD, Ghulam J. Mufti, Pierre Fenaux, MD PhD, Rena Buckstein, MD FRCPC, Valeria Santini, MD, María Díez-Campelo, MD PhD, Carlo Finelli, Mario Cazzola, MD, Osman Ilhan, Mikkael A. Sekeres, MD MS, Alan F. List, MD, Abderrahmane Laadem, Rodrigo Ito, Jennie Zhang, Anita Rampersad, Daniel Sinsimer, Peter G. Linde, Uwe Platzbecker, MD, Rami Komrokji

Blood (2019) 134 (Supplement_1): 4243.

https://doi.org/10.1182/blood-2019-123048

Published: 2019

Journal Articles

A Phase 2 Study of Luspatercept in Patients with Myelofibrosis-Associated Anemia

Blood (2019) 134 (Supplement_1): 557.

https://doi.org/10.1182/blood-2019-122546

Published: 2019

Journal Articles

Luspatercept Significantly Reduces Red Blood Cell (RBC) Transfusion Burden, Regardless of Gene Mutation Frequency, Spectrum, and Prognostic Significance, Among Patients (Pts) with LR-MDS Enrolled in the MEDALIST Trial

Blood (2019) 134 (Supplement_1): 2999.

https://doi.org/10.1182/blood-2019-123655

Published: 2019

Journal Articles

A Longitudinal Study in Elderly Patients with Non-Transfusion Dependent Thalassemia (NTDT) Emphasizes the Size of Splenomegaly Predicts Transfusion Requirement Later in Life

Supachai Ekwattanakit, PhDMD, Vip Viprakasit, MD DPhil

Blood (2019) 134 (Supplement_1): 2250.

https://doi.org/10.1182/blood-2019-122296

Published: 2019

Journal Articles

Effects of Luspatercept on Iron Overload and Impact on Responders to Luspatercept: Results from the BELIEVE Trial

John Porter, Maria Domenica Cappellini, MD, Thomas Coates, MD, Olivier Hermine, Vip Viprakasit, MD DPhil, Ersi Voskaridou, Hong Keng Liew, Silverio Perrotta, Abderrahim Khelif, Antonis Kattamis, Abderrahmane Laadem, Jeevan K. Shetty, Wen-Ling Kuo, Dimana Miteva, Tatiana Zinger, Peter G. Linde, Daniel Sinsimer, Ali Taher

Blood (2019) 134 (Supplement_1): 2245.

https://doi.org/10.1182/blood-2019-122561

Published: 2019

Journal Articles

Altered Structure and Function of Mesenchymal Stromal Cell-Derived Extracellular Matrix in MDS Can be Restored By Luspatercept

Manja Wobus, PhD, Anna Mies, Valentina Magno, PhD, Cindy Welzel, Susann Winter, PhD, Friedrich Stoelzel, MD, Carsten Werner, PhD, Martin Bornhaeuser, MD, Uwe Platzbecker, MD

Blood (2019) 134 (Supplement_1): 1699.

https://doi.org/10.1182/blood-2019-129814

Published: 2019

Journal Articles

Evaluating Luspatercept Responders in the Phase 3, Randomized, Double-Blind, Placebo-Controlled BELIEVE Trial of Luspatercept in Adult Beta-Thalassemia Patients (Pts) Who Require Regular Red Blood Cell (RBC) Transfusions

Blood (2019) 134 (Supplement_1): 3545.

https://doi.org/10.1182/blood-2019-122685

Published: 2019

Journal Articles

Effect of Rap-536 on MDS PDX-Murine Models with or without SF3B1 Mutation

Mathieu Meunier, Camille Knosp, Chloe Friedrich, Johanna Zannoni, Jean-Yves Cahn, MD PhD, Olivier Kosmider, PharmD, PhD, Michaela Fontenay, MD PhD, Sophie Park, MD PhD

Blood (2019) 134 (Supplement_1): 1705.

https://doi.org/10.1182/blood-2019-128407

Published: 2019

Journal Articles

Assessment of Longer-Term Efficacy and Safety in the Phase 3, Randomized, Double-Blind, Placebo-Controlled MEDALIST Trial of Luspatercept to Treat Anemia in Patients (Pts) with Revised International Prognostic Scoring System (IPSS-R) Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions

Blood (2019) 134 (Supplement_1): 841.

https://doi.org/10.1182/blood-2019-123064

Published: 2019

Journal Articles

Clinical Effectiveness of Hypomethylating Agents (HMAs) and Lenalidomide (Len) in Older Patients (pts) with Refractory Anemia with Ring Sideroblasts: A Large Population-Based Study in the United States (US)

Xiaoyi Wang, MD MPH, Rong Wang, PhD, Chi Zhang, MD MPH, Amer M. Zeidan, MBBS, MHS, Nikolai A. Podoltsev, MD PhD, Scott F. Huntington, MD MPH, Steven D. Gore, MD, Amy J Davidoff, PhD MS, Xiaomei Ma, PhD

Blood (2019) 134 (Supplement_1): 4748.

https://doi.org/10.1182/blood-2019-128821

Published: 2019

Journal Articles

GDF11 is not the target of luspatercept

Clara Camaschella

Blood (2019) 134 (6): 500–501.

https://doi.org/10.1182/blood.2019001983

Published: 2019

Journal Articles

Luspatercept improves hemoglobin levels and blood transfusion requirements in a study of patients with β-thalassemia

Antonio Piga, Silverio Perrotta, Maria Rita Gamberini, Ersi Voskaridou, Angela Melpignano, Aldo Filosa, Vincenzo Caruso, Antonello Pietrangelo, Filomena Longo, Immacolata Tartaglione, Caterina Borgna-Pignatti, Xiaosha Zhang, Abderrahmane Laadem, Matthew L. Sherman, Kenneth M. Attie

Blood (2019) 133 (12): 1279–1289.

https://doi.org/10.1182/blood-2018-10-879247

Published: 2019

Includes: Supplemental data

Journal Articles

Luspatercept for the treatment of anemia in myelodysplastic syndromes and primary myelofibrosis

Pierre Fenaux, Jean Jacques Kiladjian, Uwe Platzbecker

Blood (2019) 133 (8): 790–794.

https://doi.org/10.1182/blood-2018-11-876888

Published: 2019

Journal Articles

Impairment of the Stromal SDF-1-Mediated Hematopoietic Support By GDF-11 in MDS Is Rescued By Luspatercept

Manja Wobus, Anna Mies, Nandini Asokan, Uta Oelschlaegel, Susann Winter, Martina Rauner, PhD, Lorenz Hofbauer, Martin Bornhäuser, Uwe Platzbecker

Blood (2018) 132 (Supplement 1): 939.

https://doi.org/10.1182/blood-2018-99-114536

Published: 2018

Journal Articles

Beyond JAK2 Inhibitors: A Systematic Review of Management Strategies for Myelofibrosis

Ali Younas Khan, MD, Nimra Iftikhar, MD, Awais Ijaz, MD, Muhammad Junaid Tariq, MD, Faiza Jamil, MD, Arshia Akbar, MD, Anum Qureshi, Jemin Aby Jose, MD, Ahmad Kamal, MD, Muhammad Abu Zar, MD, Madeeha Shafqat, Insija Ilyas Selene, MBBS, Shehroz Aslam, MD, Faiz Anwer, MD

Blood (2018) 132 (Supplement 1): 5484.

https://doi.org/10.1182/blood-2018-99-115867

Published: 2018

Journal Articles

The Medalist Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions

Blood (2018) 132 (Supplement 1): 1.

https://doi.org/10.1182/blood-2018-99-110805

Published: 2018

Journal Articles

Mutational Profile and Analysis of Lower-Risk Myelodysplastic Syndromes (MDS) Patients Treated with Luspatercept: Phase 2 PACE-MDS Study

Uwe Platzbecker, MD, Philipp Kiewe, Ulrich Germing, MD, Katharina S. Götze, MD, Karin Mayer, MD, Markus P. Radsak, MD, Thomas Wolff, MD, Joerg Chromik, Dawn Wilson, Xiaosha Zhang, PhD, Chris Rovaldi, MSc, Abderrahmane Laadem, MD, Matthew Leigh Sherman, MD, Kenneth Morris Attie, MD, Joseph Reynolds, PhD, Peter Guest Linde, MD, Aristoteles Giagounidis, MD

Blood (2017) 130 (Supplement 1): 2982.

https://doi.org/10.1182/blood.V130.Suppl_1.2982.2982

Published: 2017

Journal Articles

Response to Erythropoietin in Different Karyotipic Subsets of Myelodysplastic Syndromes (MDS) and MDS with Sideroblasts: Multicentric Real-Life Experience from the Grom-L Cooperative Group

Blood (2017) 130 (Supplement 1): 4262.

https://doi.org/10.1182/blood.V130.Suppl_1.4262.4262

Published: 2017

Journal Articles

Sotatercept (ACE-011) Alone and in Combination with Ruxolitinib in Patients (pts) with Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis (MF) and Anemia

Prithviraj Bose, MD, Naval Daver, MD, Naveen Pemmaraju, MD, Elias J. Jabbour, MD, Zeev Estrov, MD, Allison Pike, RN, Julie Huynh-Lu, Physician Assistant, Madeleine Nguyen-Cao, Physician Assistant, Xuemei Wang, Lingsha Zhou, Sherry Pierce, BSN, BA, Hagop M. Kantarjian, MD, Srdan Verstovsek, MD PhD

Blood (2017) 130 (Supplement 1): 255.

https://doi.org/10.1182/blood.V130.Suppl_1.255.255

Published: 2017

Journal Articles

Luspatercept Increases Hemoglobin and Reduces Transfusion Burden in Patients with Low-Intermediate Risk Myelodysplastic Syndromes (MDS): Long-Term Results from Phase 2 PACE-MDS Study

Uwe Platzbecker, MD, Ulrich Germing, Katharina Götze, Philipp Kiewe, MD, Thomas Wolff, MD, Karin Mayer, MD, Joerg Chromik, MD, Markus Radsak, MD, Eileen Donovan, Dawn M. Wilson, Xiaosha Zhang, Abderrahmane Laadem, MD, Matthew L. Sherman, MD, Kenneth M. Attie, MD, Aristoteles Giagounidis

Blood (2016) 128 (22): 3168.

https://doi.org/10.1182/blood.V128.22.3168.3168

Published: 2016

NARROW

A Phase 2 Study of Luspatercept in Patients with Myelofibrosis-Associated Anemia

Luspatercept Significantly Reduces Red Blood Cell (RBC) Transfusion Burden, Regardless of Gene Mutation Frequency, Spectrum, and Prognostic Significance, Among Patients (Pts) with LR-MDS Enrolled in the MEDALIST Trial

A Longitudinal Study in Elderly Patients with Non-Transfusion Dependent Thalassemia (NTDT) Emphasizes the Size of Splenomegaly Predicts Transfusion Requirement Later in Life

Effects of Luspatercept on Iron Overload and Impact on Responders to Luspatercept: Results from the BELIEVE Trial

Altered Structure and Function of Mesenchymal Stromal Cell-Derived Extracellular Matrix in MDS Can be Restored By Luspatercept

Evaluating Luspatercept Responders in the Phase 3, Randomized, Double-Blind, Placebo-Controlled BELIEVE Trial of Luspatercept in Adult Beta-Thalassemia Patients (Pts) Who Require Regular Red Blood Cell (RBC) Transfusions

Effect of Rap-536 on MDS PDX-Murine Models with or without SF3B1 Mutation

Clinical Effectiveness of Hypomethylating Agents (HMAs) and Lenalidomide (Len) in Older Patients (pts) with Refractory Anemia with Ring Sideroblasts: A Large Population-Based Study in the United States (US)

GDF11 is not the target of luspatercept

Luspatercept improves hemoglobin levels and blood transfusion requirements in a study of patients with β-thalassemia

Luspatercept for the treatment of anemia in myelodysplastic syndromes and primary myelofibrosis

Impairment of the Stromal SDF-1-Mediated Hematopoietic Support By GDF-11 in MDS Is Rescued By Luspatercept

Beyond JAK2 Inhibitors: A Systematic Review of Management Strategies for Myelofibrosis

The Medalist Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions

Mutational Profile and Analysis of Lower-Risk Myelodysplastic Syndromes (MDS) Patients Treated with Luspatercept: Phase 2 PACE-MDS Study

Response to Erythropoietin in Different Karyotipic Subsets of Myelodysplastic Syndromes (MDS) and MDS with Sideroblasts: Multicentric Real-Life Experience from the Grom-L Cooperative Group

Sotatercept (ACE-011) Alone and in Combination with Ruxolitinib in Patients (pts) with Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis (MF) and Anemia

Luspatercept Increases Hemoglobin and Reduces Transfusion Burden in Patients with Low-Intermediate Risk Myelodysplastic Syndromes (MDS): Long-Term Results from Phase 2 PACE-MDS Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only